Welcome to chemicalbook!
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

Ripasudil hydrochloride dihydrate

Ripasudil hydrochloride dihydrate Structure
  • ₹0
  • Product name: Ripasudil hydrochloride dihydrate
  • CAS: 887375-67-9
  • MF: C15H21ClFN3O3S
  • MW: 377.86
  • EINECS:
  • MDL Number:MFCD26960897
  • Synonyms:K-115 HCL;Ripasudil free base;RipasudilHCl Hydrate;K115 HCl Dihydrate;RIPASUDIL HYDROCHLORIDE HYDRATE;(2S)-1-[(4-Fluoro-5-isoquinolinyl)sulfonyl]hexahydro-2-methyl-1H-1,4-diazepine monohydrochloride dihydrate;K-115 (HCl H2O);Ripasudil HCl Dihydrate
Manufacturer Product number Product description Packaging Price Updated Buy

Properties

storage temp. :Store at -20°C
solubility :insoluble in EtOH; ≥123.2 mg/mL in DMSO; ≥41.7 mg/mL in H2O
form :solid
color :White to off-white
Stability :Hygroscopic

Safety Information

Symbol(GHS):
Signal word:
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
Precautionary statements:

Description

Ripasudil hydrochloride hydrate (Glanatec®) was approved in Japan in 2014 for the treatment of glaucoma and ocular hypertension. Originally discovered by D. Western Therapeutics Institute, Inc. and licensed by the Kowa Company, Ltd, ripasudil functions as a selective Rho-kinase inhibitor and reduces intraocular pressure by stimulation of aqueous humour drainage of the trabecular meshwork. While this recent approval allows for use of ripasudil as a twice-daily monotherapy treatment when other drugs cannot be used or are not effective, clinical trials using ripasudil as a combination therapy with other glaucoma drugs have shown promising results in the treatment of primary open-angle glaucoma or ocular hypertension. Currently, the Kowa Company is also pursuing trials focused on the use of ripasudil for the treatment of diabetic retinopathy and diabetic macular edema.